IVERIC bio (ISEE) Stock Price
IVERIC bio Price
Revenue has compounded at 72.0% per year over the past 3 years to 209.98 M USD. IVERIC bio's net margin stands at 54.4%, up from -238.0% several years earlier.
IVERIC bio stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
IVERIC bio business model & stock analysis
Frequently asked questions about IVERIC bio
The business model of Iveric Bio Inc is focused on developing and commercializing novel therapeutics to treat serious retinal diseases. With a strong emphasis on ophthalmic drug development, Iveric Bio aims to advance innovative therapies that address unmet medical needs in eye care. By leveraging its expertise in retinal biology and genetics, the company is dedicated to identifying, developing, and bringing to market potential treatments for age-related macular degeneration (AMD) and other retinal diseases. Iveric Bio's business model revolves around research, clinical development, regulatory activities, and collaborations to provide innovative solutions for patients with vision-threatening conditions.
Iveric Bio Inc is primarily active in the biotechnology industry.
The main competitors of Iveric Bio Inc in the market include Genentech, Regeneron Pharmaceuticals, and Novartis.
Iveric Bio Inc is a biopharmaceutical company specializing in the discovery and development of novel therapies for retinal diseases. Founded in 2014, the company is headquartered in New York City, USA. Iveric Bio focuses on innovative treatments for conditions such as age-related macular degeneration (AMD) and orphan inherited retinal diseases. They have a strong commitment to advancing therapies that could potentially improve the lives of patients with vision loss. With a diverse pipeline of investigational drug candidates, Iveric Bio continues to contribute to the advancement of ophthalmic research and strives to become a leader in the field of retinal disease therapeutics.
Some significant milestones achieved by Iveric Bio Inc include the successful completion of Phase 3 clinical trials for Zimura, their leading investigational therapy for geographic atrophy, a form of age-related macular degeneration (AMD). The company has also received Fast Track designation from the U.S. FDA for Zimura in this indication. Additionally, Iveric Bio Inc has secured patents for novel technologies and treatment approaches related to retinal diseases. These achievements highlight the company's commitment to advancing innovative therapies for patients with AMD and other retinal disorders.
Iveric Bio Inc is primarily present in the United States.
Iveric Bio Inc represents values of innovation, commitment, and excellence in the biopharmaceutical industry. With a strong corporate philosophy focused on developing novel therapies for ophthalmic diseases, Iveric Bio Inc aims to improve the lives of patients worldwide. The company's dedicated research and development efforts prioritize advancing treatments for vision-threatening conditions, such as age-related macular degeneration and inherited retinal diseases. Iveric Bio Inc's commitment to cutting-edge technologies, strategic partnerships, and a patient-centric approach underscores its mission to address unmet medical needs and deliver impactful solutions in the field of eye care.
14 analysts currently rate the IVERIC bio stock: 0 recommend buying, 11 holding and 3 selling.
The IVERIC bio share (ISEE) is listed on 5 stock exchanges, including: NASDAQ (ISEE), SIX (Zürich) (O2T.SW), Frankfurt (O2T.F), München (O2T.MU), Düsseldorf (O2T.DU).
Iveric Bio Inc. is a US-based company specializing in the development and marketing of novel therapeutics for various eye diseases. The company was founded in 2019 by spinning off from the existing company Ophthotech, which took over the research and development for Iveric Biopharma. The business model of Iveric Bio Inc. revolves around the research, development, and marketing of therapeutics focusing on various eye diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and geographic atrophy (GA). AMD is the leading cause of blindness in older individuals in developed countries, while DR and GA are considered common complications in diabetic patients. The company is divided into three main divisions. The first division focuses on the development of novel therapeutic agents for various eye diseases. This division advances various preparations, including Zimura (avacincaptad pegol), which is a new class of medication for AMD treatment. This preparation aims to inhibit a specific component, Complement Factor C5, which plays a key role in the immune system functioning in the retina and causes inflammation. The second division of Iveric Bio Inc.'s business model relates to the licensing of technologies aimed at the discovery and development of new therapeutics for various eye diseases. Kyverstis is the company's main licensing program, concentrating on the preclinical development of novel therapeutics for AMD, diabetic retinopathy, and GA. The third division of Iveric Bio Inc. is the 'EIGENKAPITAL KOMPLEMENT' program. This initiative uses new technologies to study cellular processes in the retina with the goal of gaining new insights into AMD development. The program aims to acquire knowledge that can contribute to the development of future therapeutics and better help patients. The company's business activities are strengthened through partnerships and collaborations, enabling Iveric Bio Inc. to advance its research, development, and marketing of products and technologies. For example, the company collaborates with leading biotechnology company Regeneron Pharmaceuticals to advance its ongoing research and development programs. Overall, Iveric Bio Inc. offers a comprehensive portfolio of innovative therapeutics, technologies, and services for the treatment of eye diseases. The company constantly strives to further develop its products and technologies to better meet the needs of patients.
The revenue cannot currently be calculated for IVERIC bio.
The profit cannot currently be calculated for IVERIC bio.
The P/E ratio cannot be calculated for IVERIC bio at the moment.
The P/S cannot be calculated for IVERIC bio currently.
The Eulerpool Quality Score for IVERIC bio is 0/10.
The ISIN of IVERIC bio is US46583P1021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IVERIC bio is A2PHLF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IVERIC bio is ISEE. The ticker symbol is used to trade IVERIC bio shares on the stock exchange.
IVERIC bio stock
IVERIC bio Peer Group
IVERIC bio Ticker
IVERIC bio FIGI
All fundamentals and in-depth analysis of IVERIC bio
Our stock analysis for IVERIC bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IVERIC bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.